Glioblastoma Multiforme Treatment Market By Treatment Modality (Surgical Resection, Radiation Therapy, Chemotherapy, Tumor Treating Fields, Targeted Therapy, Immunotherapy, Local Radiation Therapy); By Delivery Platform (Systemic Therapy, Local/Intratumoral Delivery, Blood-Brain Barrier Delivery Technologies, Convection-Enhanced Delivery, Focused Ultrasound-Mediated Delivery); By Disease Stage (Newly Diagnosed GBM, Recurrent GBM); By Molecular Profile (MGMT-Methylated GBM, MGMT-Unmethylated GBM, IDH-Wildtype GBM, Other Biomarker-Defined GBM); By End User (Hospitals, Neuro-Oncology Centers, Specialty Cancer Centers, Academic and Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Glioblastoma Multiforme Treatment Market: Survival Ceiling, Device Adherence, and BBB Delivery Push Revenue Beyond Conventional Chemotherapy

The Global Glioblastoma Multiforme (GBM) Treatment Market was valued at USD 3.72 billion in 2025 and is projected to reach USD 8.32 billion by 2032, expanding at a CAGR of 12.2%, according to Strategic Market Research.

 

Glioblastoma multiforme treatment remains one of the highest-unmet-need areas in oncology because standard therapy has produced only limited survival gains despite decades of drug development. CBTRUS reported that glioblastoma represented 13.7% of all primary brain and CNS tumors and 52.2% of malignant brain and CNS tumors in the U.S., making it the dominant malignant primary brain tumor subtype. An estimated 13,930 new glioblastoma cases were expected in the U.S. in 2025. Patient volume is smaller than in lung, breast, colorectal, or prostate cancer, but treatment intensity is high because GBM requires neurosurgery, radiation, chemotherapy, molecular testing, MRI surveillance, supportive care, recurrence management, and trial-based intervention.

 

Global treatment demand should be assessed within the broader brain and central nervous system (CNS) cancer care infrastructure rather than glioblastoma multiforme (GBM) incidence alone. According to IARC’s GLOBOCAN 2024 estimates, brain and CNS cancers accounted for 324,095 new cases and 248,964 deaths worldwide. Although these figures extend beyond GBM, they provide a clear indication of where capacity expansion is required across neurosurgery, radiation oncology, neuroimaging, molecular pathology, and advanced drug-delivery systems. Asia represents the largest absolute disease burden, while the U.S. and Western Europe continue to function as higher-value markets due to well-established tertiary neuro-oncology centers, stronger reimbursement pathways, broader device access, and mature clinical trial networks.

 

Standard Therapy Still Sets the Revenue Floor

Maximal safe surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide continues to serve as the standard treatment foundation for newly diagnosed glioblastoma multiforme (GBM). The NCI PDQ outlines standard management as maximal safe surgery, radiation therapy administered with daily temozolomide, followed by six cycles of adjuvant temozolomide. The pivotal regimen used 60 Gy radiotherapy over six weeks with temozolomide during radiation, followed by adjuvant cycles after a treatment break. Hospitals therefore continue to generate baseline treatment demand through neurosurgical resection, radiation planning, oral chemotherapy, anti-seizure care, steroid management, and serial MRI follow-up.

Temozolomide continues to retain clinical relevance because it is firmly integrated into the glioblastoma treatment pathway, despite its limited ability to address disease recurrence. The landmark radiotherapy-plus-temozolomide regimen improved median overall survival to 14.6 months versus 12.1 months with radiotherapy alone. Two-year survival improved to 26.5% from 10.4%. NCI PDQ also reports three-year overall survival of 16.0% with radiotherapy plus temozolomide versus 4.4% with radiotherapy alone. These gains established temozolomide as standard care, but survival remains short enough to keep demand high for add-on devices, delivery technologies, immunotherapy, and recurrent-disease products.

Dose intensification has not meaningfully broadened the clinical or commercial opportunity for chemotherapy. Evidence from a phase III study summarized by the NCI showed no statistically significant survival benefit with dose-dense adjuvant temozolomide compared with standard adjuvant temozolomide, with median overall survival of 16.6 months versus 14.9 months, respectively. As a result, reformulation or dosing modifications are unlikely to generate substantial value unless they demonstrate clear advantages in drug delivery, toxicity reduction, combination compatibility, or clinical benefit within a defined molecular subgroup.

MGMT promoter methylation remains a clinically important biomarker for identifying the glioblastoma population most likely to derive benefit from temozolomide. NCI PDQ reports that, in the EORTC-NCIC companion analysis, patients with MGMT promoter methylation achieved a median overall survival of 18.2 months, compared with 12.2 months among patients without methylation. This survival differential reinforces the unmet need in MGMT-unmethylated glioblastoma, where the therapeutic benefit of standard chemotherapy is more limited. As a result, this subgroup continues to be a major focus for vaccine-based approaches, immunotherapy combinations, blood-brain barrier–opening strategies, and novel drug delivery platforms.

Modern molecular classification is also reshaping how glioblastoma trials and treatment populations are evaluated. Adult glioblastoma is now defined as an IDH-wildtype disease entity, while tumors previously described as IDH-mutant glioblastoma are classified separately as astrocytoma, IDH-mutant, WHO grade 4. For drug developers, combining these molecularly distinct groups in clinical trials can distort efficacy interpretation, as IDH-mutant grade 4 astrocytoma has different tumor biology, prognosis, and treatment response patterns. Therefore, molecularly defined trial design is increasingly critical for regulatory credibility, payer confidence, and investor assessment of therapeutic value.

 

Tumor Treating Fields Created the Strongest Approved Add-On Pathway

Tumor Treating Fields gave GBM treatment a rare approved survival-improving add-on outside conventional drug therapy. FDA’s PMA record lists Optune with temozolomide for adults aged 22 years or older with newly diagnosed supratentorial GBM after maximal debulking surgery and completion of radiation therapy with concomitant standard chemotherapy. Device-based treatment shifts spending toward equipment, transducer arrays, patient training, remote support, adherence monitoring, replacement supplies, and payer authorization.

EF-14 continues to serve as the pivotal commercial and clinical validation point for Tumor Treating Fields (TTFields) in glioblastoma management. In the randomized trial, TTFields plus maintenance temozolomide demonstrated a median progression-free survival of 6.7 months compared with 4.0 months for temozolomide alone. Median overall survival improved to 20.9 months versus 16.0 months, while long-term follow-up showed a five-year survival rate of 13% compared with 5%. These outcomes established Novocure’s differentiated position in newly diagnosed glioblastoma; however, real-world uptake remains closely linked to patient tolerance, treatment compliance, and sustained daily device use.

Adherence remains the primary practical limitation for TTFields therapy. Patients are required to wear scalp arrays for prolonged daily durations, manage visible device components, address potential skin irritation, and adapt to lifestyle disruption during a clinically vulnerable phase of neurologic disease. In EF-14, mild-to-moderate skin toxicity was reported in 52% of patients receiving TTFields, while grade 3 skin toxicity occurred in 2%. As a result, centers with structured patient education, nursing support, reimbursement assistance, and remote adherence monitoring are better positioned to translate clinical eligibility into sustained therapeutic use.

Novocure’s broader TTFields expansion into other cancers gives the platform wider oncology visibility, but GBM remains the category where the technology has its deepest clinical identity. Recent FDA approval of Tumor Treating Fields in pancreatic cancer may help validate the modality across solid tumors, while GBM continues to test whether device adherence can hold under real-world neuro-oncology conditions.

 

Recurrent GBM Keeps Treatment Spending High but Outcomes Weak

Recurrent glioblastoma multiforme (GBM) represents one of the most challenging clinical and commercial segments within neuro-oncology. Most patients relapse after surgery, radiation, and temozolomide, while many are not candidates for repeat surgery because of tumor location, neurologic decline, performance status, or diffuse recurrence. NCI PDQ notes that re-resection is limited to selected patients, and repeat radiation remains difficult because evidence is limited and neurocognitive risks are meaningful.

Bevacizumab retains a defined role in recurrent GBM because it can reduce edema, steroid dependence, and radiographic burden. FDA granted accelerated approval for bevacizumab monotherapy in progressive glioblastoma in 2009. Supporting phase II evidence showed tumor responses in 26% of patients in one study, with median response duration of 4.2 months, and responses in 20% of patients in another study, with median duration of 3.9 months. Bevacizumab remains clinically useful in selected recurrent cases, but survival benefit has not been proven in prospective randomized GBM trials.

First-line bevacizumab did not create a larger newly diagnosed GBM franchise. RTOG 0825 and AVAglio showed progression-free survival improvement when bevacizumab was added to radiotherapy and temozolomide, but neither trial produced an overall-survival gain. Avastin therefore remains more relevant as a recurrence-management tool than as a broad first-line growth driver.

Checkpoint inhibition has also failed to convert GBM into a standard immuno-oncology market. CheckMate 143 reported no survival improvement with nivolumab versus bevacizumab in recurrent GBM, with median overall survival of 9.8 months versus 10.0 months. Objective response was lower with nivolumab than with bevacizumab. GBM’s immune-excluded environment, steroid exposure, tumor heterogeneity, and CNS-specific biology have limited the success of systemic checkpoint therapy.

Regorafenib’s GBM AGILE setback further narrowed the path for repurposed targeted therapy. The adaptive platform trial reported no overall-survival improvement in recurrent GBM or newly diagnosed unmethylated GBM, and the regorafenib arm was stopped for limited efficacy. Negative platform-trial results reduce weak development paths and push investment toward therapies with stronger biology, delivery advantage, or molecular selection.

 

BBB Delivery Has Become a Core Development Problem

GBM drug development is increasingly shifting from target selection alone toward optimizing therapeutic delivery and tumor-site exposure. The blood-brain barrier, infiltrative tumor growth, intratumoral heterogeneity, and immunosuppressive microenvironment limit the effectiveness of many systemic agents. GBM cells extend beyond visible enhancing disease, leaving surgery and radiation unable to eliminate microscopic invasion. Therapies that improve brain penetration, local drug exposure, or intratumoral immune activation have stronger rationale than conventional systemic add-ons.

Focused ultrasound is one of the more practical delivery technologies because it opens the blood-brain barrier temporarily and may improve access for existing or future therapies. A multicenter phase 1/2 trial evaluated microbubble-enhanced transcranial focused ultrasound with temozolomide in high-grade glioma and reported feasible BBB opening with exploratory survival signals. Randomized confirmation is still needed, but focused ultrasound could add a procedural revenue layer to chemotherapy, biologics, nanoparticles, or immune-based agents if safety and repeatability hold.

Localized radiation and intratumoral approaches are also drawing investment in recurrent disease. Alpha Tau’s Alpha DaRT program uses localized alpha radiation delivered into tumor tissue. The company reported U.S. interim data in 2026 from the REGAIN recurrent GBM trial, including local disease-control and complete-response signals in treated lesions. Company-reported interim data require caution, but the approach is commercially relevant because recurrent GBM patients often have few local options and procedure-based therapy fits specialized neurosurgical and radiation-oncology centers.

Carmustine wafers show that localized GBM therapy has long had clinical interest, even if adoption has stayed limited. Newer local-delivery strategies must show better placement accuracy, patient selection, repeatability, and neurologic safety. Products that require implantation, image guidance, convection-enhanced delivery, or intratumoral administration will depend on high-volume centers rather than broad community oncology use.

 

Immunotherapy Is Shifting Toward Local and Personalized Designs

GBM immunotherapy is moving away from standard checkpoint-inhibitor assumptions and toward vaccines, multi-target cell therapy, oncolytic viruses, and local immune activation. Systemic checkpoint therapy has not delivered meaningful survival benefit in recurrent GBM, so developers are targeting tumor heterogeneity, antigen escape, CNS delivery, and immunosuppressive myeloid biology more directly.

Personalized vaccine strategies are being evaluated in molecularly high-risk glioblastoma populations, particularly where existing standard-of-care approaches provide limited clinical benefit. In a 2026 Nature Cancer phase 1 study, the personalized neoantigen DNA vaccine GNOS-PV01 was assessed in patients with newly diagnosed MGMT-unmethylated GBM. The study reported a median progression-free survival of 8.5 months, median overall survival of 16.3 months, and a 24-month survival rate of 33% in a small treated cohort, supporting continued investigation of vaccine-based immunotherapy in this difficult-to-treat subgroup. Early sample size limits commercial interpretation, but MGMT-unmethylated GBM remains one of the most important development settings because temozolomide benefit is weaker.

CAR-T development is moving toward multiple targets and CNS-directed delivery. University of Pennsylvania and Gilead/Kite reported phase 1 recurrent GBM data using intrathecal bivalent CAR-T cells targeting EGFR and IL13Rα2. Tumors shrank in 8 of 13 measurable patients, or 62%, among 18 treated patients, although many responses were temporary and neurotoxicity occurred. Multi-target CAR-T designs address antigen heterogeneity more directly than single-target approaches, but durability, safety, manufacturing time, and administration logistics remain major barriers.

Oncolytic viruses are emerging as immune-activating therapeutic platforms for recurrent glioblastoma. Dana-Farber reported phase 1 data in 41 recurrent GBM patients using an engineered oncolytic herpes simplex virus, with immune-cell recruitment into tumors and survival longer than historical outcomes in selected patients. Controlled trials will decide whether these programs can move beyond early academic interest. Commercial adoption would depend on intratumoral delivery logistics, combination compatibility, and evidence of durable benefit after relapse.

Next-generation targets such as GPNMB remain at the preclinical stage but indicate the evolving direction of GBM cell-therapy development. A 2026 Nature preclinical study identified GPNMB in both GBM tumor cells and immunosuppressive myeloid cells, and anti-GPNMB CAR-T showed disease-control activity in models. Human efficacy is not established, but dual tumor-and-microenvironment targeting could become attractive if early clinical programs validate the biology.

 

Orphan Designations Keep the Pipeline Active but Do Not Reduce Evidence Risk

FDA orphan drug designations remain attractive for GBM sponsors due to small patient populations, high unmet need, and regulatory incentives that can strengthen development economics. Cintredekin besudotox received orphan drug designation for glioblastoma in 2025. The therapy targets IL-13 receptor alpha-2–expressing cells, although prior randomized phase 3 convection-enhanced delivery testing failed to improve survival versus carmustine in recurrent GBM. Revived assets will require improved delivery precision, refined patient selection, and clear survival benefit to restore commercial confidence.

Exosome-based therapy also received FDA orphan drug designation for malignant glioma in 2025, according to healthcare-industry coverage. Exosome platforms are attractive because they are positioned around biologic delivery across difficult barriers, but human efficacy, biodistribution, scalable manufacturing, and safety remain unresolved. Investors and partners will continue to apply heavy risk discounts until early signals translate into controlled clinical results.

 

Regional Adoption Depends on Neuro-Oncology Capacity

The U.S. leads the GBM treatment market because neurosurgery, radiation oncology, molecular diagnostics, FDA device pathways, specialty reimbursement, and academic trial networks are concentrated in the same care system. Nearly 14,000 annual U.S. GBM diagnoses provide a stable base for temozolomide use, TTFields adoption, recurrent GBM drug treatment, device-enabled delivery trials, CAR-T studies, and vaccine programs.

Europe has strong neuro-oncology expertise and clinical-trial infrastructure, but adoption depends on country-level reimbursement and specialist-center access. TTFields, molecular testing, advanced radiotherapy, vaccine trials, and local-delivery procedures are easier to scale in systems with established academic hospitals and organized referral networks. Germany, France, the UK, Italy, Spain, and Nordic countries remain priority markets because they combine registry capacity, radiation infrastructure, neuro-oncology centers, and multinational trial participation.

Asia Pacific carries the largest absolute brain/CNS cancer burden but uneven GBM treatment access. Japan, South Korea, Australia, Singapore, and major Chinese urban centers have advanced neurosurgical and oncology services. Lower-resource settings continue to face gaps in MRI access, radiation capacity, molecular pathology, and trial availability. Regional growth will depend on infrastructure investment, reimbursement expansion, and access to high-volume neuro-oncology centers rather than disease burden alone.

 

Competitive Positioning

Merck’s temozolomide legacy remains central to newly diagnosed GBM treatment, although generic competition limits branded upside. Roche/Genentech retains recurrent GBM relevance through Avastin, especially where edema control and steroid reduction are major clinical needs. Novocure holds the strongest device position through Optune, with GBM still serving as the core proof market for Tumor Treating Fields.

Gilead/Kite and academic partners are shaping the cell-therapy conversation through multi-target CAR-T work, but durability, neurotoxicity, manufacturing complexity, and CNS delivery remain major barriers. Vaccine developers are targeting MGMT-unmethylated and other molecularly defined groups where standard chemotherapy leaves larger treatment gaps. Alpha Tau is pursuing procedure-based local radiation in recurrent disease. Focused-ultrasound developers are trying to turn BBB modulation into repeatable delivery infrastructure for chemotherapy, biologics, or future combinations.

 

Analyst View

Glioblastoma multiforme treatment is being reshaped by device-based survival extension, molecularly segmented chemotherapy value, recurrent-disease failures, and delivery-led innovation. Standard surgery, radiotherapy, and temozolomide will remain the treatment floor, but meaningful commercial upside is shifting toward TTFields, BBB-opening systems, local radiation, personalized vaccines, CAR-T cells, oncolytic viruses, and exosome or nanocarrier platforms.

TTFields has the strongest approved non-drug position because EF-14 produced survival benefit and the FDA-cleared pathway is already established in newly diagnosed GBM. Adoption depends on adherence, payer coverage, patient acceptance, skin toxicity management, and physician confidence after chemoradiation.

Drug developers have the best opportunity in MGMT-unmethylated newly diagnosed GBM, recurrent GBM after standard therapy, and delivery-enabled treatment settings where conventional systemic exposure is inadequate. Personalized vaccines, multi-target CAR-T cells, oncolytic viruses, focused ultrasound, exosomes, and alpha-radiation approaches are relevant because they address immune resistance, tumor heterogeneity, or CNS penetration.

The most important indicators to track are randomized overall survival, durable recurrent-disease response, steroid-sparing benefit, neurocognitive outcomes, MGMT and IDH-defined trial design, TTFields adherence, focused-ultrasound safety, CAR-T persistence, local-delivery feasibility, orphan-designation follow-through, and regulatory acceptance of early-phase signals. GBM remains a high-risk oncology category, but companies that solve delivery, selection, and workflow problems have a stronger path than companies relying on broad pipeline activity.

 

Glioblastoma Multiforme (GBM) Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.72 Billion
Revenue Forecast in 2032	USD 8.32 Billion
Overall Growth Rate	CAGR of 12.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Modality, By Delivery Platform, By Disease Stage, By Molecular Profile, By End User, By Geography
By Treatment Modality	Surgical Resection, Radiation Therapy, Chemotherapy, Tumor Treating Fields, Targeted Therapy, Immunotherapy, Local Radiation Therapy
By Delivery Platform	Systemic Therapy, Local/Intratumoral Delivery, Blood-Brain Barrier Delivery Technologies, Convection-Enhanced Delivery, Focused Ultrasound-Mediated Delivery
By Disease Stage	Newly Diagnosed GBM, Recurrent GBM
By Molecular Profile	MGMT-Methylated GBM, MGMT-Unmethylated GBM, IDH-Wildtype GBM, Other Biomarker-Defined GBM
By End User	Hospitals, Neuro-Oncology Centers, Specialty Cancer Centers, Academic and Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Rising glioblastoma incidence Limited survival outcomes from existing therapies Increasing adoption of Tumor Treating Fields
Customization Option	Available upon request